Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Genelux Corp (NASDAQ: GNLX) closed the day trading at $2.72 down -19.76% from the previous closing price of $3.39. In other words, the price has decreased by -$19.76 from its previous closing price. On the day, 1.88 million shares were traded. GNLX stock price reached its highest trading level at $3.0 during the session, while it also had its lowest trading level at $2.655.
Ratios:
For a better understanding of GNLX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.20 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In the most recent recommendation for this company, Lake Street on October 21, 2025, initiated with a Buy rating and assigned the stock a target price of $16.
On October 29, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $8.
On August 28, 2024, ROTH MKM started tracking the stock assigning a Buy rating and target price of $10.ROTH MKM initiated its Buy rating on August 28, 2024, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 21 ’25 when Yu Yong sold 3,219 shares for $3.36 per share. The transaction valued at 10,807 led to the insider holds 146,817 shares of the business.
Yu Yong sold 973 shares of GNLX for $5,224 on Nov 17 ’25. The SVP, Clinical Development now owns 145,844 shares after completing the transaction at $5.37 per share. On Aug 21 ’25, another insider, Zindrick Thomas, who serves as the President and CEO of the company, sold 12,673 shares for $3.33 each. As a result, the insider received 42,159 and left with 542,940 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GNLX now has a Market Capitalization of 103500824 and an Enterprise Value of 83031152.
Stock Price History:
The Beta on a monthly basis for GNLX is 0.19, which has changed by 0.31395352 over the last 52 weeks, in comparison to a change of 0.1877265 over the same period for the S&P500. Over the past 52 weeks, GNLX has reached a high of $8.53, while it has fallen to a 52-week low of $1.99. The 50-Day Moving Average of the stock is -46.85%, while the 200-Day Moving Average is calculated to be -29.33%.
Shares Statistics:
Over the past 3-months, GNLX traded about 235.11K shares per day on average, while over the past 10 days, GNLX traded about 169250 shares per day. A total of 37.61M shares are outstanding, with a floating share count of 33.12M. Insiders hold about 12.97% of the company’s shares, while institutions hold 30.67% stake in the company. Shares short for GNLX as of 1765756800 were 3080437 with a Short Ratio of 13.10, compared to 1763078400 on 2953521. Therefore, it implies a Short% of Shares Outstanding of 3080437 and a Short% of Float of 8.270001.
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of Genelux Corp (GNLX) in the stock market.The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.19 and low estimates of -$0.26.
Analysts are recommending an EPS of between -$0.83 and -$0.87 for the fiscal current year, implying an average EPS of -$0.85. EPS for the following year is -$0.95, with 6.0 analysts recommending between -$0.81 and -$1.18.
